Identification of key regions and genes important in the pathogenesis of Sézary syndrome by combining genomic and expression microarrays

Cancer Research

Volumn 69, Issue 21, 2009, Pages 8438-8446

  Caprini, Elisabetta ^a   Cristofoletti, Cristina ^a   Arcelli, Diego ^a   Fadda, Paolo ^a   Citterich, Mauro Helmer ^a   Sampogna, Francesca ^a   Magrelli, Armando ^b   Censi, Federica ^b   Torreri, Paola ^b   Frontani, Marina ^a   Scala, Enrico ^a   Picchio, Maria Cristina ^a   Temperani, Paola ^c   Monopoli, Alessandro ^a   Lombardo, Giuseppe Alfonso ^a   Taruscio, Domenica ^b   Narducci, Maria Grazia ^a   Russo, Giandomenico ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BAG4 GENE; BTRC GENE; BUB3 GENE; CANCER SURVIVAL; CHROMOSOME 10P; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME 8Q; CHROMOSOME 9Q; CHROMOSOME ABERRATION; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; MICROARRAY ANALYSIS; NKIRAS2 GENE; PIP5K1B GENE; PRIORITY JOURNAL; PSMD3 GENE; SEZARY SYNDROME; SINGLE NUCLEOTIDE POLYMORPHISM; TRAF2 GENE;

CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN; COMPARATIVE GENOMIC HYBRIDIZATION; GENE DOSAGE; GENE EXPRESSION PROFILING; HUMANS; LOSS OF HETEROZYGOSITY; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEZARY SYNDROME; SURVIVAL RATE;

EID: 70350542803     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-2367     Document Type: Article

References (50)

1. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105: 3768-3785
2. Mao X, Lillington DM, Czepulkowski B, Russell-Jones R, Young BD, Whittaker S. Molecular cytogenetic characterization of Sezary syndrome. Genes Chromosomes Cancer 2003;36:250-260 (Pubitemid 36158198)
3. Vermeer MH, van Doorn R, Dijkman R, et al. Novel and highly recurrent chromosomal alterations in Sezary syndrome. Cancer Res 2008;68:2689-2698 (Pubitemid 351556266)
4. Tracey L, Villuendas R, Dotor AM, et al. Mycosis fungoides shows concurrent deregulation of multiple genes involved in the TNF signaling pathway: an expression profile study. Blood 2003;102:1042-1050 (Pubitemid 36917802)
5. Kari L, Loboda A, Nebozhyn M, et al. Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma. J Exp Med 2003; 197:1477-1488 (Pubitemid 36682545)
6. van Doorn R, Dijkman R, Vermeer MH, et al. Aberrant expression of the tyrosine kinase receptor EphA4 and the transcription factor twist in Sezary syndrome identified by gene expression analysis. Cancer Res 2004;64: 5578-5586 (Pubitemid 39095552)
7. Nigro JM, Misra A, Zhang L, et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res 2005;65: 1678-1686 (Pubitemid 40478592)
8. Tsafrir D, Bacolod M, Selvanayagam Z, et al. Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res 2006;66:2129-2137 (Pubitemid 43294922)
9. Walker BA, Leone PE, Jenner MW, et al. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood 2006; 108:1733-1743
10. Wolf M,Mousses S,Hautaniemi S, et al. High-resolution analysis of gene copy number alterations in human prostate cancer using CGH on cDNA microarrays: impact of copy number on gene expression. Neoplasia 2004;6: 240-247
11. Lastowska M, Viprey V, Santibanez-Koref M, et al. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data. Oncogene 2007;26:7432-7444 (Pubitemid 350158715)
12. Mao X, McElwaine S. Functional copy number changes in Sezary syndrome: toward an integrated molecular cytogenetic map III. Cancer Genet Cytogenet 2008;185:86-94.
13. van Doorn R, van Kester MS, Dijkman R, et al. Oncogenomic analysis of mycosis fungoides reveals major differences with Sezary syndrome. Blood 2009; 113:127-136
14. Popescu NC, Zimonjic DB. Molecular cytogenetic characterization of cancer cell alterations. Cancer Genet Cytogenet 1997;93:10-21. (Pubitemid 27102484)
15. Zhao X, Li C, Paez JG, et al. An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res 2004;64:3060-3071 (Pubitemid 38581405)
16. Narducci MG, Scala E, Bresin A, et al. Skin homing of Sezary cells involves SDF-1-CXCR4 signaling and down-regulation of CD26/dipeptidylpeptidase IV. Blood 2006; 107:1108-1115 (Pubitemid 43156312)
17. Scala E, Narducci MG, Amerio P, et al. T cell receptor- Vβ analysis identifies a dominant CD60+ CD26-CD49d- T cell clone in the peripheral blood of Sezary syndrome patients. J Invest Dermatol 2002;119:193-196
18. Lin M, Wei LJ, Sellers WR, Lieberfarb M, Wong WH, Li C. dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data. Bioinformatics 2004;20:1233-1240 (Pubitemid 38807579)
19. Arcelli D, Palmieri A, Pezzetti F, Brunelli G, Zollino I, Carinci F. Genetic effects of a titanium surface on osteoblasts: a meta-analysis. J Oral Sci 2007;49:299-309.
20. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci US A 2001;98:5116-5121 (Pubitemid 32397092)
21. Wang TL, Maierhofer C, Speicher MR, et al. Digital karyotyping. Proc Natl Acad Sci US A 2002;99:16156-16161
22. Janne PA, Li C, Zhao X, et al. High-resolution single-nucleotide polymorphism array and clustering analysis of loss of heterozygosity in human lung cancer cell lines. Oncogene 2004;23:2716-2726 (Pubitemid 38586325)
23. Kotzot D. Complex and segmental uniparental disomy (UPD): review and lessons from rare chromosomal complements. J Med Genet 2001;38:497-507. (Pubitemid 32751577)
24. Pollack JR, Sorlie T, Perou CM, et al. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci US A 2002;99: 12963-12968
25. Higgins ME, Claremont M, Major JE, Sander C, Lash AE. CancerGenes: a gene selection resource for cancer genome projects. Nucleic Acids Res 2007;35:D721-6. (Pubitemid 46056298)
26. Batista DA, Vonderheid EC, Hawkins A, et al. Multi-color fluorescence in situ hybridization (SKY) in mycosis fungoides and Sezary syndrome: search for recurrent chromosome abnormalities. Genes Chromosomes Cancer 2006;45:383-391 (Pubitemid 43346770)
27. Espinet B, Salido M, Pujol RM, et al. Genetic characterization of Sezary's syndrome by conventional cytogenetics and cross-species color banding fluorescent in situ hybridization. Haematologica 2004;89:165-173 (Pubitemid 38796490)
28. Fischer TC, Gellrich S, Muche JM, et al. Genomic aberrations and survival in cutaneous T cell lymphomas. J Invest Dermatol 2004;122:579-586 (Pubitemid 38471321)
29. Karenko L, Kahkonen M, Hyytinen ER, Lindlof M, Ranki A. Notable losses at specific regions of chromosomes 10q and 13q in the Sezary syndrome detected by comparative genomic hybridization. J Invest Dermatol 1999;112:392-395 (Pubitemid 29125121)
30. Scarisbrick JJ, Woolford AJ, Russell-Jones R, Whittaker SJ. Allelotyping in mycosis fungoides and Sezary syndrome: common regions of allelic loss identified on 9p, 10q, and 17p. J Invest Dermatol 2001;117:663-670 (Pubitemid 32955595)
31. Thangavelu M, Finn WG, Yelavarthi KK, et al. Recurring structural chromosome abnormalities in peripheral blood lymphocytes of patients with mycosis fungoides/ Sezary syndrome. Blood 1997;89:3371-3377 (Pubitemid 27229824)
32. Fitzgibbon J, Smith LL, Raghavan M, et al. Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res 2005;65:9152-9154 (Pubitemid 41507976)
33. Mao X, Orchard G, Vonderheid EC, et al. Heterogeneous abnormalities of CCND1 and RB1 in primary cutaneous T-Cell lymphomas suggesting impaired cell cycle control in disease pathogenesis. J Invest Dermatol 2006;126:1388-1395 (Pubitemid 43997923)
34. Scarisbrick JJ, Woolford AJ, Calonje E, et al. Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome. J Invest Dermatol 2002; 118:493-499 (Pubitemid 34227167)
35. Durig J, Bug S, Klein-Hitpass L, et al. Combined single nucleotide polymorphism-based genomic mapping and global gene expression profiling identifies novel chromosomal imbalances, mechanisms and candidate genes important in the pathogenesis of T-cell prolymphocytic leukemia with inv(14)(q11q32). Leukemia 2007;21:2153-2163
36. Hyman E, Kauraniemi P, Hautaniemi S, et al. Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res 2002;62:6240-6245 (Pubitemid 35244477)
37. Mao X, Lillington D, Scarisbrick JJ, et al. Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sezary syndrome and mycosis fungoides. Br J Dermatol 2002; 147:464-475 (Pubitemid 35015279)
38. Wang Y, Putnam CD, Kane MF, et al. Mutation in Rpa1 results in defective DNA double-strand break repair, chromosomal instability and cancer in mice. Nat Genet 2005;37:750-755 (Pubitemid 41754893)
39. Izban KF, Ergin M, Qin JZ, et al. Constitutive expression of NF-κB is a characteristic feature of mycosis fungoides: implications for apoptosis resistance and pathogenesis. Hum Pathol 2000;31:1482-1490 (Pubitemid 32047000)
40. Sors A, Jean-Louis F, Pellet C, et al. Down-regulating constitutive activation of the NF-κB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood 2006;107:2354-2363 (Pubitemid 43345555)
41. Karenko L, Sarna S, Kahkonen M, Ranki A. Chromosomal abnormalities in relation to clinical disease in patients with cutaneous T-cell lymphoma: a 5-year follow-up study. Br J Dermatol 2003;148:55-64. (Pubitemid 36114862)
42. Logarinho E, Resende T, Torres C, Bousbaa H. The human spindle assembly checkpoint protein Bub3 is required for the establishment of efficient kinetochore-microtubule attachments. Mol Biol Cell 2008;19:1798-1813 (Pubitemid 351805130)
43. Chan GK, Yen TJ. The mitotic checkpoint: a signaling pathway that allows a single unattached kinetochore to inhibit mitotic exit. Prog Cell Cycle Res 2003;5:431-439
44. Canela N, Rodriguez-Vilarrupla A, Estanyol JM, et al. The SET protein regulates G2/M transition by modulating cyclin B-cyclin-dependent kinase 1 activity. J Biol Chem 2003;278:1158-1164 (Pubitemid 36790797)
45. Cervoni N, Detich N, Seo SB, Chakravarti D, Szyf M. The oncoprotein Set/TAF-1β, an inhibitor of histone acetyltransferase, inhibits active demethylation of DNA, integrating DNA methylation and transcriptional silencing. J Biol Chem 2002;277:25026-25031 (Pubitemid 34951806)
46. Li M, Makkinje A, Damuni Z. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem 1996;271:11059-11062 (Pubitemid 26155931)
47. Okuwaki M, Nagata K. Template activating factor-I remodels the chromatin structure and stimulates transcription from the chromatin template. J Biol Chem 1998;273:34511-34518 (Pubitemid 29008932)
48. Thebault S, Roudbaraki M, Sydorenko V, et al. α1- adrenergic receptors activate Ca(2+)-permeable cationic channels in prostate cancer epithelial cells. J Clin Invest 2003;111:1691-1701
49. Lacalle RA, Peregil RM, Albar JP, et al. Type I phosphatidylinositol 4-phosphate 5-kinase controls neutrophil polarity and directional movement. J Cell Biol 2007;179:1539-1553
50. Vicente-Manzanares M, Sanchez-Madrid F. Role of the cytoskeleton during leukocyte responses. Nat Rev Immunol 2004;4:110-122